Ro Peptides: What the GLP-1 Offering Covers

This article lives in the PlexusDx Education Hub, our library on GLP-1 therapies, weight management protocols, and the genetic variables behind every metabolic decision. Browse all Peptides & GLP-1 education

Independent editorial note: PlexusDx offers its own peptide-based program and has no affiliate arrangement or commercial relationship with Ro. This overview is unsponsored.

"Ro peptides" points to the class of molecules behind modern weight-management programs. GLP-1 medications are themselves peptides, and understanding the category clarifies what any telehealth service is really offering to a customer. This editorial gives a plain overview of the peptide landscape and how Ro’s model fits it. Current as of April 2026.

The peptide class behind GLP-1 programs

The medications driving these programs are peptide-based: GLP-1 receptor agonists such as semaglutide, liraglutide, and dulaglutide, and the GIP and GLP-1 dual agonist tirzepatide. Their weight-management evidence traces to trial programs including STEP for semaglutide (NEJM, 2021) and SURMOUNT for tirzepatide (NEJM, 2022). The pharmacology of any credible program is set by this underlying compound class, and the differences between a single-pathway agonist and a dual agonist matter more than any brand name. Understanding that the medication is a peptide, not a stimulant or a generic diet pill, is the first step to reading these programs accurately.

What a peptide-based offering includes

Ro (Roman Health) is a subscription telehealth service. A peptide-based offering in this model generally bundles a clinical evaluation, a prescription for a GLP-1 peptide, fulfillment through either a retail or a 503A compounding pharmacy, and follow-up as doses are titrated. The specific peptides available, the dosing formats, and the pricing are posted by the brand itself, and they change over time; review the current details at Ro's official website.

Compounded peptides and the 503A pathway

When a peptide is compounded rather than dispensed as an FDA-approved brand product, it is prepared by a 503A compounding pharmacy for a specific patient on a clinician’s prescription. This is a lawful, regulated route that is clearly distinct from ordinary retail dispensing. Knowing whether a program supplies branded or compounded peptides clarifies both the regulatory pathway and what you can expect on cost. It also explains why availability and price can shift over time, since branded and compounded supply respond to different pressures.

The peptide genetics telehealth skips

A peptide prescription rarely accounts for the biology it acts on. Variants in FTO, the fat-mass and obesity-associated gene, and GLP1R, the receptor these peptides target, map the terrain a compound operates within. They are pathway-level markers that do not predict response to any peptide. The Precision Peptide Genetic Test reads 14 pathways, 49 peptides, 150+ genetic insights, including FTO, MC4R, and TCF7L2, describing the appetite-regulation and energy-balance biology behind the class.

The PlexusDx peptide-genetics approach

PlexusDx builds its Weight Management Protocols around the same peptide class, offered as Semaglutide Injection and Tirzepatide Injection, and pairs them with the Precision Peptide Genetic Test. The peptide is only half the picture; the genetic context is the half most programs leave out, which is why the two are offered together rather than separately.

Not affiliated: PlexusDx has no commercial relationship with Ro or any company referenced here.

More from the PlexusDx library: What Is GLP-1, GLP-1 What Is, GLP-1 Receptor Agonist, GLP-1 Drugs.

Editorial disclaimer: this article is educational. PlexusDx is not affiliated with Ro and offers semaglutide and tirzepatide through its own Weight Management Protocols. The Precision Peptide Genetic Test analyzes how genes influence peptide-related pathways and does not predict response to any specific medication. Consult a qualified healthcare provider before starting any peptide protocol.

Compare the PlexusDx route: review the Weight Management Protocols, which pair semaglutide and tirzepatide with genetic context most telehealth-only programs leave out. Or begin upstream and take the Precision Peptide Genetic Test to map your GLP-1 pathway first.

Frequently Asked Questions about Ro peptides

Are GLP-1 medications considered peptides?

Yes. Semaglutide, liraglutide, dulaglutide, and tirzepatide are peptide-based molecules that act on incretin receptors. GLP-1 receptor agonists engage one pathway, while tirzepatide engages both GIP and GLP-1. The class defines the pharmacology behind any credible weight-management telehealth program.

What is the difference between branded and compounded peptides?

A branded peptide is an FDA-approved product dispensed at retail, while a compounded peptide is a patient-specific preparation from a 503A pharmacy on a clinician’s order. Both use the same active molecule but travel different regulatory and supply routes, which affects cost and availability.

Does a genetic test predict peptide results?

No. The Precision Peptide Genetic Test maps pathway-level variants in FTO and MC4R, and TCF7L2 that shape baseline biology. It does not forecast how any peptide will perform for you; it adds upstream context for a more informed conversation with your provider.

Which peptides does PlexusDx offer?

PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols, in injection and oral formats, paired with the Precision Peptide Genetic Test. The approach combines the peptide compound with pathway-level genetic context rather than dispensing it in isolation.

Keep exploring the PlexusDx Education Hub. Browse all Peptides & GLP-1 education